Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Sanofi boosts vaccines with a $685 million investment
by Rick Mullin
June 20, 2020
| A version of this story appeared in
Volume 98, Issue 24
Sanofi plans to spend $550 million on a vaccine-manufacturing facility in Neuville-sur-Saône, France, a 5-year project expected to create 200 full-time jobs. Sanofi will also invest $135 million in an R&D facility in Marcy-l’Étoile. Geared toward meeting production needs in any future pandemics, the plant will feature a central unit housing several modules that can make 3–4 vaccines simultaneously. Sanofi and GlaxoSmithKline announced in April that they are collaborating on the development of an adjuvanted COVID-19 vaccine, for which the French firm will contribute an antigen based on recombinant DNA technology.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X